本文旨在确定活痘苗-gp160病毒疫苗免疫和加强免疫后诱导的细胞免疫应答的范围和持久性。 研究对象为无种痘史、未感染过人类免疫缺陷症病毒（HIV）的18～60岁男性健康志愿者。用作疫苗的痘苗-gp160制剂是包含HIV LAI包膜糖蛋白完整编码序列的重组痘苗V-env Ny5病毒,浓度为2±1×10~7噬斑形成单位（pfu）/ml和2±1×10~8pfu/ml,用分叉针划痕接种。对照制剂为天花疫苗。加强免疫的制剂为杆状病毒产生的经纯化的gp160（rgp160）,剂量为640μg。分别于0、14、28、54、70、90、120、180、270和365天采血,分离血清和单个核细胞（MNL）。用ELISA和蛋白印迹法检测血清阳转情况;用各种细胞免疫试验对MNL进行检测,包括淋巴细胞增殖、γ干扰素（IFN-γ）产生以及细胞毒T淋巴细胞（CTL）活性试验。用杆状病毒表达的rgp160作为体外刺激MNL的HIV-1抗原,用植物血凝素（PHA）作为阳性对照刺激物。CTL活性试验用补骨脂素灭活的HIV（PI-HIV,1μg/ml）刺激MNL、培养7～10天 This article aims to determine the range and persistence of live vaccinia-gp160 virus vaccination and boost of cellular immune responses induced after immunization. The subjects were healthy volunteers aged 18 to 60 years who had no history of vaccination and who had not been infected with human immunodeficiency virus (HIV). The vaccinia-gp160 formulation used as a vaccine is a recombinant vaccinia V-env Ny5 virus containing the complete coding sequence of the HIV LAI envelope glycoprotein at a concentration of 2 ± 1 x 10 ~ 7 plaque forming units (pfu) / ml and 2 ± 1 × 10 ~ 8pfu / ml, with a bifurcated needle scratch inoculation. The control preparation is a smallpox vaccine. The boosted preparation was baculovirus-generated purified gp160 (rgp160) at a dose of 640 μg. Blood and mononuclear cells (MNLs) were collected at 0, 14, 28, 54, 70, 90, 120, 180, 270 and 365 days respectively. Serum samples were detected by ELISA and western blotting. MNL was detected by various cellular immunity assays including lymphocyte proliferation, IFN-γ production and cytotoxic T lymphocyte (CTL) activity. Baculovirus-expressed rgp160 was used as HIV-1 antigen to stimulate MNL in vitro, and phytohemagglutinin (PHA) was used as a positive control stimulus. CTL Activity Assay MNL was stimulated with psoralen-inactivated HIV (PI-HIV, 1 μg / ml) and cultured for 7 to 10 days